NCT06344832
SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs No drug interventions Not Available Not Available not_yet_recruiting NCT04282083
Protocol ITANET - Registry No drug interventions Not Available Not Available recruiting NCT02736500
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors treatment 1 / 2 unknown_status NCT04837885
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases treatment 2 recruiting NCT02736448
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors treatment 2 unknown_status NCT05364944
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) treatment 1 active_not_recruiting NCT05385861
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET treatment 1 / 2 enrolling_by_invitation NCT06356467
Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs No drug interventions Not Available Not Available recruiting NCT05709171
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms diagnostic 2 enrolling_by_invitation NCT05477576
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy treatment 3 recruiting NCT06253897
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly No drug interventions Not Available Not Available recruiting NCT03972488
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET treatment 3 active_not_recruiting NCT05050942
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET treatment 3 active_not_recruiting NCT01423734
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases No drug interventions Not Available Not Available completed NCT03600233
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors treatment 2 active_not_recruiting NCT03475953
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors treatment 1 / 2 recruiting NCT03863106
The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours No drug interventions Not Available Not Available unknown_status NCT03220217
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) diagnostic 2 completed NCT02779257
Pasireotide Treatment for Neuroendocrine Tumor treatment 4 withdrawn NCT04614766
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors treatment 1 / 2 withdrawn NCT03042780
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas treatment 2 terminated NCT02150408
Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors No drug interventions diagnostic Not Available completed NCT05048901
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors treatment 1 / 2 recruiting NCT02788565
Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours No drug interventions Not Available Not Available completed NCT04852679
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs treatment 3 completed NCT04609592
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery treatment 1 recruiting NCT06256705
Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort No drug interventions other Not Available recruiting NCT05262556
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas treatment 1 active_not_recruiting NCT04986085
Nutrition in Gastroenteropancreatic Neuroendocrine Tumor No drug interventions Not Available Not Available completed NCT06155318
68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours No drug interventions Not Available Not Available recruiting NCT05701241
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients treatment 4 recruiting NCT02611024
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors treatment 1 / 2 recruiting NCT03980925
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. treatment 2 active_not_recruiting NCT04727723
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs Not Available Not Available active_not_recruiting NCT03017690
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) No drug interventions Not Available Not Available completed NCT01994213
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor treatment 2 terminated NCT05987176
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases treatment 2 recruiting NCT04915144
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs treatment 2 withdrawn NCT02948946
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors No drug interventions Not Available Not Available completed NCT05064150
Neuroendocrine Tumors - Patient Reported Outcomes No drug interventions Not Available Not Available enrolling_by_invitation NCT05359146
Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) basic_science 0 recruiting NCT04524442
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients other 4 completed NCT03043664
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors treatment 1 / 2 completed NCT02078843
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors diagnostic 1 / 2 terminated NCT02630654
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs No drug interventions Not Available Not Available completed NCT04711135
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs treatment 2 active_not_recruiting NCT01842165
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs treatment 3 completed NCT02730104
Community-based Neuroendocrine Tumor (NET) Research Study No drug interventions Not Available Not Available completed NCT02162446
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET diagnostic 1 / 2 completed NCT02608203
[68 Ga]-DOTANOC PET/CT in GEP-NETs No drug interventions diagnostic 2 / 3 completed NCT02231762
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET treatment 2 completed NCT06402695
Observational Study on GEP-and Pulm-NET Treated at FPG No drug interventions Not Available Not Available recruiting NCT05448157
68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET No drug interventions Not Available Not Available active_not_recruiting